Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Bioo Scientific's NextFlex Barcodes; Life Tech's HID-Ion AmpliSeq Panel; More

Premium

Bioo Scientific has launched its NextFlex Dual Indexed DNA Barcodes, designed for multiplexing of up to 192 samples for next-generation sequencing. The barcodes can be used to multiplex genomic DNA, RNA, or ChIP-seq libraries and allows users to pool multiple library preparations in a single flow cell lane.


Life Technologies has launched its HID-Ion AmpliSeq Identity Panel, a next-gen sequencing-based SNP panel for human identification research applications. The panel is run on the Ion Torrent PGM system. It requires 1 ng of input DNA and has a turnaround time of 1.5 days. The panel includes 30 upper Y-Clade SNPs and 90 autosomal SNPs that have high heterozygosity and low Fst that were selected from publications by Yale University's Kenneth Kidd and the SNPforID Consortium.


Eppendorf has released its epMotion automation method for Illumina's TruSeq Stranded Total RNA library preparation as "Illumina Qualified," meaning that the method creates libraries that perform comparably to ones prepared manually.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.